SCHEDULE 13G/A 0001140361-24-024395 0001403525 XXXXXXXX LIVE 1 Common Shares 09/30/2025 0001771910 ADC Therapeutics SA H0036K147 Biopole Route de la Corniche 3B Epalinges V8 1066 Rule 13d-1(c) Oaktree Fund Administration, LLC DE 0 4673441 0 4673441 4673441 N 4.14 OO The reported securities represent 4,409,794 shares of Common Stock and 263,647 shares of Common Stock issuable upon exercise of warrants to acquire shares of Common Stock ("Warrants"). The reported percentage is calculated based on (i) 112,499,395 shares of Common Stock outstanding as of August 1, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on August 12, 2025, as increased by (ii) 263,647 Common Stock issuable in respect of the Warrants. Oaktree Capital Holdings, LLC DE 0 4673441 0 4673441 4673441 N 4.14 OO The reported securities represent 4,409,794 shares of Common Stock and 263,647 shares of Common Stock issuable upon exercise of Warrants. The reported percentage is calculated based on (i) 112,499,395 shares of Common Stock outstanding as of August 1, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on August 12, 2025, as increased by (ii) 263,647 Common Stock issuable in respect of the Warrants. Oaktree Capital Group Holdings GP, LLC DE 0 4673441 0 4673441 4673441 N 4.14 OO The reported securities represent 4,409,794 shares of Common Stock and 263,647 shares of Common Stock issuable upon exercise of Warrants. The reported percentage is calculated based on (i) 112,499,395 shares of Common Stock outstanding as of August 1, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on August 12, 2025, as increased by (ii) 263,647 Common Stock issuable in respect of the Warrants. Brookfield Asset Management ULC A1 0 0 0 0 0 N 0 OO The reporting person which previously reported together with the Oaktree Reporting Persons, has been determined to no longer act together with the Oaktree Reporting Persons, and therefore has ceased to be the beneficial owner of any securities covered by this Statement. Brookfield Corporation A6 0 0 0 0 0 N 0 OO The reporting person which previously reported together with the Oaktree Reporting Persons, has been determined to no longer act together with the Oaktree Reporting Persons, and therefore has ceased to be the beneficial owner of any securities covered by this Statement. Brookfield Asset Management, Ltd. A1 0 0 0 0 0 N 0 OO The reporting person which previously reported together with the Oaktree Reporting Persons, has been determined to no longer act together with the Oaktree Reporting Persons, and therefore has ceased to be the beneficial owner of any securities covered by this Statement. BAM Partners Trust A6 0 0 0 0 0 N 0 OO The reporting person which previously reported together with the Oaktree Reporting Persons, has been determined to no longer act together with the Oaktree Reporting Persons, and therefore has ceased to be the beneficial owner of any securities covered by this Statement. ADC Therapeutics SA Biopole, Route de la Corniche 3B, Epalinges, Switzerland, 1066 This statement is filed by the entities and persons listed below, all of whom together are referred to herein as the "Reporting Persons": (i) Oaktree Fund Administration, LLC ("Fund Admin."); (ii) Oaktree Capital Holdings, LLC ("OCH"), a Delaware limited liability, in its capacity as the indirect manager of Fund Admin.; (iii) Oaktree Capital Group Holdings GP, LLC ("OCGH," and together with Fund Admin. and OCH, the "Oaktree Reporting Persons"), a Delaware limited liability company, in its capacity as an indirect owner of OCH; (iv) Brookfield Asset Management ULC, a British Columbia corporation ("Brookfield ULC"), in its capacity as an indirect owner of OCH; (v) Brookfield Asset Management Ltd. ("BAM"), a British Columbia company, in its capacity as an owner of Brookfield ULC; (vi) Brookfield Corporation, an Ontario corporation, in its capacity as an owner of BAM; and (vii) BAM Partners Trust (together with Brookfield ULC, Brookfield Corporation, and BAM, the "Brookfield Reporting Persons"), an Ontario trust, in its capacity as the sole owner of the Class B Shares of each of Brookfield Corporation and BAM. The principal business address of each of the Oaktree Reporting Persons is 333 S. Grand Avenue, 28th Floor, Los Angeles, CA 90071. The principal business address of each of the Brookfield Reporting Persons is 181 Bay Street, Suite 100, Brookfield Place, Toronto, Ontario, Canada M5J 2T3. See responses to Item 4 on each cover page. Y See responses to Item 9 on each cover page. See responses to Item 11 on each cover page. See responses to Item 5 on each cover page. See responses to Item 6 on each cover page. See responses to Item 7 on each cover page. See responses to Item 8 on each cover page. N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Oaktree Fund Administration, LLC /s/ Henry Orren 11/05/2025 Oaktree Capital Holdings, LLC /s/ Henry Orren 11/05/2025 Oaktree Capital Group Holdings GP, LLC /s/ Henry Orren 11/05/2025 Brookfield Asset Management ULC /s/ Kathy Sarpash 11/05/2025 Brookfield Corporation /s/ Swati Mandava 11/05/2025 Brookfield Asset Management, Ltd. /s/ Kathy Sarpash 11/05/2025 BAM Partners Trust /s/ Kathy Sarpash 11/05/2025